Has Dipna Pharmachem declared dividend?

No Dividend History Available

What is the technical trend for Dipna Pharmachem?

As of June 2, 2025, Dipna Pharmachem's technical trend is mildly bullish, supported by strong weekly indicators and bullish Bollinger Bands, but tempered by mixed monthly signals and a mildly bearish outlook from Dow Theory.

As of 2 June 2025, the technical trend for Dipna Pharmachem has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The RSI shows no signal on the weekly chart and is bearish on the monthly chart, suggesting weakening momentum. Bollinger Bands are bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, Dow Theory indicates a mildly bearish trend on the weekly chart, which adds caution. Overall, the current technical stance is mildly bullish, driven by strong weekly indicators but tempered by monthly bearish signals.

Who are the peers of the Dipna Pharmachem?

Dipna Pharmachem's peers include Vasundhara Rasy., Vivo Bio Tech, Godavari Drugs, Concord Drugs, Lasa Supergeneri, Medi Caps, Shelter Pharma, Transchem, and Sandu Pharma. Dipna Pharmachem leads in 1-year returns at 203.59%, significantly outperforming its peers.

Peers: The peers of Dipna Pharmachem are Vasundhara Rasy., Vivo Bio Tech, Godavari Drugs, Concord Drugs, Lasa Supergeneri, Medi Caps, Shelter Pharma, Transchem, and Sandu Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shelter Pharma, while Average management risk is found at Vasundhara Rasy., Vivo Bio Tech, Godavari Drugs, Medi Caps, and Transchem. Below Average management risk is noted for Concord Drugs, Lasa Supergeneri, Dipna Pharmachem, Sandu Pharma, and the rest. Growth is Excellent for Dipna Pharmachem, Below Average for Vasundhara Rasy., Vivo Bio Tech, Godavari Drugs, Concord Drugs, Lasa Supergeneri, Medi Caps, Transchem, and Sandu Pharma, and Good for Shelter Pharma. Capital Structure is Good for Vasundhara Rasy. and Medi Caps, Average for Lasa Supergeneri, Below Average for Vivo Bio Tech, Godavari Drugs, Concord Drugs, Dipna Pharmachem, Transchem, and Sandu Pharma, and Excellent for Shelter Pharma.<BR><BR>Return Snapshot: Dipna Pharmachem has the highest 1-year return at 203.59%, while Lasa Supergeneri has the lowest at -49.73%. Dipna Pharmachem's return significantly outperforms all peers. Additionally, the six-month return is negative for Lasa Supergeneri, Medi Caps, and Shelter Pharma.

Who are in the management team of Dipna Pharmachem?

As of March 2022, the management team of Dipna Pharmachem includes Keyur Shah (Managing Director), Dipna Shah (Director), Nandish Jani, Chinu Kalal, and Jitendra Parmar (Independent Directors), along with Khushboo Jethaliya and Madhuri Gurwani (Company Secretaries & Compliance Officers).

As of March 2022, the management team of Dipna Pharmachem includes the following individuals:<BR><BR>1. Keyur Shah - Managing Director<BR>2. Dipna Shah - Director<BR>3. Nandish Jani - Independent Director<BR>4. Chinu Kalal - Independent Director<BR>5. Khushboo Jethaliya - Company Secretary & Compliance Officer<BR>6. Jitendra Parmar - Independent Director<BR>7. Madhuri Gurwani - Company Secretary & Compliance Officer<BR><BR>These members play various roles in the governance and management of the company.

What does Dipna Pharmachem do?

Dipna Pharmachem Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2011 and transitioned to public status in 2022. It currently has no reported sales or profit data, with a market cap of INR 60 Cr.

Overview:<BR>Dipna Pharmachem Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Dipna Pharmachem Private Limited was incorporated in 2011 and changed its name to Dipna Pharmachem Private Limited in 2012. The company transitioned from Private Limited to Public Limited status and was renamed Dipna Pharmachem Limited on May 25, 2022. There is no recent sales or profit data reported.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 60 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 57.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.15<BR>Return on Equity: 2.59%<BR>Price-to-Book: 1.60<BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A<BR>Email: N/A<BR>Website: N/A

Who are the top shareholders of the Dipna Pharmachem?

The top shareholders of Dipna Pharmachem include promoter Keyur Dipakkumar Shah with 9.97% and public shareholder Teena Kirti Jain with 4.1%. Individual investors hold a significant 71.21% of the shares, with no institutional holdings reported.

The top shareholders of Dipna Pharmachem include Keyur Dipakkumar Shah, who is the promoter with the highest holding at 9.97%. The highest public shareholder is Teena Kirti Jain, holding 4.1%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 71.21% of the shares. There are no institutional holdings from mutual funds or foreign institutional investors.

How big is Dipna Pharmachem?

As of 23rd July, Dipna Pharmachem Ltd has a market capitalization of 59.00 Cr, categorizing it as a Micro Cap company. Financial data for the latest quarterly performance is unavailable, but as of March 2024, Shareholder's Funds are 37.52 Cr and Total Assets are 132.90 Cr.

As of 23rd July, Dipna Pharmachem Ltd has a market capitalization of 59.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>There is no valid financial data available for the latest quarterly performance, including Net Sales and Net Profit for the latest four quarters.<BR><BR>The reporting period for the balance sheet is March 2024, with Shareholder's Funds amounting to 37.52 Cr and Total Assets valued at 132.90 Cr.

When is the next results date for Dipna Pharmachem?

Dipna Pharmachem will announce its results on 26 November 2025.

Dipna Pharmachem will declare its results on 26 November 2025.

Is Dipna Pharmachem overvalued or undervalued?

As of November 21, 2025, Dipna Pharmachem is considered overvalued due to a high PE ratio of 41.87 and low ROE of 2.52%, despite a strong one-year stock return of 150.22%, especially when compared to peers like Sun Pharma and Cipla.

As of 21 November 2025, Dipna Pharmachem's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently considered overvalued based on its high PE ratio of 41.87, an EV to EBIT ratio of 16.69, and a ROE of only 2.52%. In comparison, peers such as Sun Pharma have a PE of 36.98 and an EV to EBITDA of 24.43, while Cipla, which is rated attractive, has a significantly lower PE of 22.45 and an EV to EBITDA of 15.88.<BR><BR>Given these ratios and the peer comparison, Dipna Pharmachem appears to be overvalued in the current market context. Despite a strong one-year stock return of 150.22%, which outperformed the Sensex's 10.47%, the company's financial metrics suggest that its stock price may not be justified at this level.

How has been the historical performance of Dipna Pharmachem?

Dipna Pharmachem has experienced a significant decline in financial performance, with net sales dropping from 727.56 Cr in March 2022 to 124.92 Cr by March 2025, alongside decreasing operating profit and negative cash flow from operations. Despite stable total liabilities, the overall trend indicates ongoing challenges in profitability and sales.

Answer:<BR>The historical performance of Dipna Pharmachem shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Dipna Pharmachem's net sales peaked at 727.56 Cr in March 2022 but have since declined to 124.92 Cr by March 2025. The total operating income followed a similar trend, dropping from 727.56 Cr in March 2022 to 124.93 Cr in March 2025. The company's operating profit (PBDIT) also saw a decline from 22.10 Cr in March 2022 to 3.45 Cr in March 2025, while profit before tax remained relatively stable at 1.42 Cr in March 2025 compared to 1.42 Cr in March 2024. Profit after tax showed a slight decrease from 1.09 Cr in March 2024 to 0.97 Cr in March 2025. The company's total liabilities have remained relatively stable, with a slight decrease from 132.90 Cr in March 2024 to 132.38 Cr in March 2025. Cash flow from operating activities has been negative, with -9.00 Cr in March 2025, indicating ongoing challenges in generating cash from operations. Overall, the financial performance of Dipna Pharmachem reflects a downward trend in sales and profitability over the past few years.

Why is Dipna Pharmachem falling/rising?

As of 21-Dec, Dipna Pharmachem Ltd's stock price is rising at Rs 14.92, with a 10.52% increase today. Despite a year-to-date return of 3.54% and a monthly decline of 13.36%, the stock has gained 108.09% over the past year, though it faces volatility and reduced investor participation.

As of 21-Dec, Dipna Pharmachem Ltd's stock price is rising, currently at Rs 14.92, reflecting a change of Rs 1.42 or 10.52% increase. This upward movement is supported by the stock's performance today, where it has outperformed the sector by 9.77% and has gained consecutively for the last two days, accumulating a total return of 11.09% during this period. Additionally, the stock touched an intraday high of Rs 15, marking an increase of 11.11%.<BR><BR>In the context of recent performance, the stock has shown a positive return of 7.88% over the past week, contrasting with a slight decline in the benchmark Sensex, which fell by 0.40%. However, it is important to note that the stock has experienced a decline of 13.36% over the past month, indicating some volatility in its performance. Despite this, the year-to-date return stands at 3.54%, which is lower than the Sensex's 8.69%, and the stock has shown a remarkable increase of 108.09% over the past year compared to the Sensex's 7.21%.<BR><BR>The stock's trading activity has been characterized by high volatility today, with an intraday volatility of 5.26%. However, there has been a notable decline in investor participation, as evidenced by a 63.41% drop in delivery volume on December 18 compared to the 5-day average. This suggests that while the stock is currently rising, there are underlying factors such as erratic trading and falling investor participation that could influence its future performance.

Why is Dipna Pharmachem falling/rising?

As of 22-Dec, Dipna Pharmachem Ltd's stock price is rising to 15.39, reflecting a 3.15% increase. The stock has shown strong recent performance, outperforming its sector and the Sensex, with a significant year-to-date gain of 6.80% and an impressive 106.30% increase over the past year.

As of 22-Dec, Dipna Pharmachem Ltd's stock price is rising, currently at 15.39, reflecting an increase of 0.47 or 3.15%. The stock has shown strong performance recently, outperforming its sector by 2.5% today and achieving a consecutive gain over the last three days, with a total return of 14.59% during this period. Additionally, the stock has experienced a significant increase in investor participation, as evidenced by a 16.28% rise in delivery volume compared to the 5-day average. <BR><BR>In the context of broader market performance, the stock has outperformed the Sensex by 10.80% over the past week, indicating positive momentum. However, it is important to note that while the stock has performed well recently, it has seen a decline of 8.88% over the past month. Despite this, the year-to-date performance remains positive at 6.80%, and the stock has shown an impressive increase of 106.30% over the past year. <BR><BR>Overall, the combination of recent gains, increased trading activity, and strong year-over-year performance contributes to the current rise in Dipna Pharmachem's stock price.

Why is Dipna Pharmachem Ltd falling/rising?

As of 23-Dec, Dipna Pharmachem Ltd's stock price is at Rs 16.59, up 7.8%, with strong recent performance and a year-to-date increase of 15.13%. Despite a drop in investor participation, the stock shows a positive upward trend.

As of 23-Dec, Dipna Pharmachem Ltd's stock price is rising, currently at Rs 16.59, reflecting an increase of Rs 1.2 or 7.8%. The stock has shown strong performance recently, outperforming the sector by 8.01% today and achieving a consecutive gain over the last four days, with a total return of 23.53% during this period. Additionally, the stock opened with a gain of 3.9% today and reached an intraday high of Rs 16.75, which is an increase of 8.84%.<BR><BR>In the context of broader performance, the stock has demonstrated significant growth year-to-date, with a 15.13% increase compared to the Sensex's 9.45%. Over the past year, it has surged by 120.32%, far exceeding the Sensex's 8.89% gain. Despite a slight decline over the past month of 1.78%, the overall trend remains positive, particularly in the short term.<BR><BR>However, it is worth noting that there has been a decrease in investor participation, with delivery volume dropping by 89.8% against the 5-day average. This could indicate a potential concern for future trading activity, but the current price movement is clearly upward.

Why is Dipna Pharmachem Ltd falling/rising?

As of 24-Dec, Dipna Pharmachem Ltd's stock price is at 16.50, down 0.54%. The stock has reversed its upward trend after four days of gains, showing weaker performance relative to longer-term averages and a significant drop in trading volume, indicating reduced investor confidence.

As of 24-Dec, Dipna Pharmachem Ltd's stock price is currently at 16.50, reflecting a decrease of 0.09 or 0.54%. The stock has experienced a trend reversal, having fallen after four consecutive days of gains. This decline is notable given that the stock's performance today is described as inline with the sector, yet it has not maintained its upward momentum.<BR><BR>In terms of moving averages, the stock is currently higher than its 5-day and 20-day moving averages but lower than its 50-day, 100-day, and 200-day moving averages, indicating a potential weakening in the stock's upward trend. Additionally, there has been a significant drop in investor participation, with delivery volume on December 23 falling by 36.17% compared to the 5-day average. This decline in trading activity may suggest reduced investor confidence or interest in the stock at its current price level.<BR><BR>Overall, while the stock has shown strong performance over longer periods, such as a 1-year increase of 82.72%, the recent short-term trends and decreased trading volume are contributing factors to its current decline.

Why is Dipna Pharmachem Ltd falling/rising?

As of 25-Dec, Dipna Pharmachem Ltd's stock price is at 16.50, down 0.54% after a trend reversal following four days of gains. The stock has seen a significant drop in investor participation and a recent decline in trading volume, indicating a potential weakening trend despite strong long-term performance.

As of 25-Dec, Dipna Pharmachem Ltd's stock price is currently at 16.50, reflecting a decrease of 0.09 or 0.54%. This decline follows a trend reversal after four consecutive days of gains. The stock's performance today is described as inline with the sector, but it is noteworthy that the stock has experienced a drop in investor participation, with delivery volume on December 23 falling by 36.17% compared to the 5-day average. <BR><BR>While the stock has shown strong performance over the longer term, with a year-to-date increase of 14.50% and a one-year increase of 82.72%, it has faced challenges recently, including a 4.68% decline over the past month. Additionally, the stock's moving averages indicate that it is currently higher than the 5-day and 20-day moving averages but lower than the longer-term 50-day, 100-day, and 200-day moving averages, suggesting a potential weakening trend. <BR><BR>Overall, the combination of a recent decline in trading volume and the trend reversal after previous gains contributes to the current falling stock price of Dipna Pharmachem Ltd.

Which are the latest news on Dipna Pharmachem?

Which are the latest news on Dipna Pharmachem?